Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature (3)
Nature Cancer (2)
Nature Communications (1)
Nature Reviews Immunology (1)
Nature Biotechnology (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (5)
Amendments and Corrections (2)
Reviews (1)

Subject Check one or more subjects to show results from those subjects only.

Biotechnology
Cancer
Chemical biology
Developmental biology
Diseases
Drug discovery
Immunology
Nanoscience and technology
Oncology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–8 of 8 results

Advanced filters: Author: Anusha Kalbasi Clear advanced filters

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer. Here, the authors develop a NLPHL specific model to identify 34 distinct cell states across 14 cell types that co-occur within 3 lymphocyte predominant ecotypes (LPEs) for 171 cases.

Ajay Subramanian
Shengqin Su
Michael Sargent Binkley
ResearchOpen Access26 Sept 2025
Nature Communications

Volume: 16, P: 1-16
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Gabriel Abril-Rodriguez
Davis Y. Torrejon
Antoni Ribas
Amendments and Corrections22 Jan 2020
Nature Cancer

Volume: 1, P: 264
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors

Anusha Kalbasi
Mikko Siurala
K. Christopher Garcia
Amendments and CorrectionsOpen Access15 Nov 2022
Nature

Volume: 612, P: E10
Potentiating adoptive cell therapy using synthetic IL-9 receptors

Synthetic chimeric orthogonal IL-2 receptors that incorporate the intracellular domain of receptors for other γ-chain cytokines such as IL-9 can reroute orthogonal signalling and alter the phenotype of T cells to improve anti-tumour responses.

Anusha Kalbasi
Mikko Siurala
K. Christopher Garcia
ResearchOpen Access08 Jun 2022
Nature

Volume: 607, P: 360-365
Expanding the cytokine receptor alphabet reprograms T cells into diverse states

Orthogonal chimeric receptors containing intracellular domains for IL-4R, IL-20R, IL-22R and GCSFR reprogram T cells to promote distinct natural and synthetic cell states with functional and therapeutic implications.

Yang Zhao
Masato Ogishi
K. Christopher Garcia
ResearchOpen Access13 Aug 2025
Nature

Volume: 645, P: 1039-1050
Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors

Gold-siRNA clusters boost the immune response of radiotherapy against primary and distant tumors.

Yuyan Jiang
Hongbin Cao
Quynh-Thu Le
Research24 Oct 2024
Nature Biotechnology

Volume: 43, P: 1496-1509
PAK4 inhibition improves PD-1 blockade immunotherapy

Ribas and colleagues report that inhibition of PAK4 improves response to anti-PD-1 immunotherapy by reducing Wnt pathway activation and increasing tumor infiltration by T cells.

Gabriel Abril-Rodriguez
Davis Y. Torrejon
Antoni Ribas
Research09 Dec 2019
Nature Cancer

Volume: 1, P: 46-58
Tumour-intrinsic resistance to immune checkpoint blockade

Understanding why some patients and not others respond to immune checkpoint blockade for cancer is crucial for extending benefit from this therapy. Here the authors describe how tumour cells can resist immune checkpoint blockade, for example, by resistance to interferon signalling and through immune-evasive oncogenic signalling pathways.

Anusha Kalbasi
Antoni Ribas
Reviews30 Sept 2019
Nature Reviews Immunology

Volume: 20, P: 25-39